FourThought Financial Partners LLC Grows Stock Holdings in Progyny, Inc. (NASDAQ:PGNY)

FourThought Financial Partners LLC raised its holdings in shares of Progyny, Inc. (NASDAQ:PGNY) by 1.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 32,683 shares of the company’s stock after buying an additional 423 shares during the quarter. FourThought Financial Partners LLC’s holdings in Progyny were worth $1,215,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in PGNY. State of Alaska Department of Revenue lifted its holdings in shares of Progyny by 4.7% in the 3rd quarter. State of Alaska Department of Revenue now owns 9,931 shares of the company’s stock valued at $337,000 after acquiring an additional 450 shares during the last quarter. Xponance Inc. boosted its holdings in shares of Progyny by 3.6% in the 3rd quarter. Xponance Inc. now owns 11,629 shares of the company’s stock worth $396,000 after purchasing an additional 399 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Progyny by 2.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 769,262 shares of the company’s stock worth $26,170,000 after purchasing an additional 20,182 shares during the period. Bailard Inc. increased its position in shares of Progyny by 8.5% during the 3rd quarter. Bailard Inc. now owns 7,700 shares of the company’s stock valued at $262,000 after purchasing an additional 600 shares during the last quarter. Finally, Brown Advisory Inc. raised its holdings in Progyny by 3.9% during the 3rd quarter. Brown Advisory Inc. now owns 10,611 shares of the company’s stock valued at $361,000 after buying an additional 403 shares during the period. 94.93% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Progyny

In other Progyny news, Chairman David J. Schlanger sold 20,000 shares of Progyny stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $38.50, for a total value of $770,000.00. Following the transaction, the chairman now owns 86,312 shares in the company, valued at $3,323,012. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Progyny news, Chairman David J. Schlanger sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $38.50, for a total value of $770,000.00. Following the completion of the sale, the chairman now directly owns 86,312 shares in the company, valued at $3,323,012. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, President Michael E. Sturmer sold 2,260 shares of the company’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $40.00, for a total value of $90,400.00. Following the transaction, the president now directly owns 158,532 shares in the company, valued at $6,341,280. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 125,030 shares of company stock valued at $4,714,385. 12.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

PGNY has been the subject of several recent analyst reports. Truist Financial reaffirmed a “buy” rating and set a $46.00 price objective on shares of Progyny in a research note on Wednesday, April 17th. Leerink Partnrs reaffirmed an “outperform” rating on shares of Progyny in a research note on Monday, February 26th. Cantor Fitzgerald reissued an “overweight” rating and issued a $48.00 price objective on shares of Progyny in a research report on Wednesday, February 28th. SVB Leerink assumed coverage on Progyny in a research report on Monday, February 26th. They set an “outperform” rating and a $49.00 target price for the company. Finally, KeyCorp cut their target price on Progyny from $45.00 to $43.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 28th. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Progyny presently has a consensus rating of “Buy” and an average price target of $48.30.

Progyny Trading Down 1.1 %

Shares of PGNY traded down $0.35 during midday trading on Friday, reaching $31.72. 760,486 shares of the stock were exchanged, compared to its average volume of 683,382. The company has a market capitalization of $3.05 billion, a P/E ratio of 51.16, a PEG ratio of 1.31 and a beta of 1.51. Progyny, Inc. has a 52 week low of $29.44 and a 52 week high of $44.95. The company’s 50 day moving average is $35.10 and its two-hundred day moving average is $35.60.

Progyny (NASDAQ:PGNY) last issued its earnings results on Tuesday, February 27th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.04. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The company had revenue of $269.94 million for the quarter, compared to analysts’ expectations of $274.08 million. During the same period in the prior year, the business earned $0.03 EPS. The firm’s quarterly revenue was up 26.0% on a year-over-year basis. On average, sell-side analysts expect that Progyny, Inc. will post 0.7 EPS for the current year.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.